Cell reprogramming therapy for Parkinson’s disease
Neural Regeneration Research · 2024-11 · 19 (11) · 2444-2455
DOI: 10.4103/1673-5374.390965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neural Regeneration Research, online erschienen am 15.12.2023. Verfasst von Wenjing Dong und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunmi…. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Parkinson’s disease is typically characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Many studies have been performed based on the supplementation of lost dopaminergic neurons to treat Parkinson’s disease. The initial strategy for cell replacement therapy used human fetal ventral midbrain and human embryonic stem cells to treat Parkinson’s disease, which could substantially alleviate the symptoms of Parkinson’s disease in clinical practice. However, ethical issues and tumor formation were limitations of its clinical application. Induced pluripotent stem cells can be acquired without sacrificing human embryos, which eliminates the huge ethical barriers of human stem cell therapy. Another widely considered neuronal regeneration strategy is to directly reprogram fibroblasts and astrocytes into neurons, without the need for intermediate proliferation states, thus avoiding issues of immune rejection and tumor formation. Both induced pluripotent stem cells and direct reprogramming of lineage cells have shown promising results in the treatment of Parkinson’s disease. However, there are also ethical concerns and the risk of tumor formation that need to be addressed. This review highlights the current application status of cell reprogramming in the treatment of Parkinson’s disease, focusing on the use of induced pluripotent stem cells in cell replacement therapy, including preclinical animal models and progress in clinical research. The review also discusses the advancements in direct reprogramming of lineage cells in the treatment of Parkinson’s disease, as well as the controversy surrounding in vivo reprogramming. These findings suggest that cell reprogramming may hold great promise as a potential strategy for treating Parkinson’s disease.
Autor:innen und Institutionen
- State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan Province, China.
- Yunnan Key Laboratory of Primate Biomedical Research, Kunming, Yunnan Province, China.
ORCID-Profile: Shangang Li, Zhengbo Wang
Zitieren
APA
Dong, W., Liu, S., Li, S., & Wang, Z. (2024). Cell reprogramming therapy for Parkinson’s disease. Neural Regeneration Research, 19(11), 2444-2455. https://doi.org/10.4103/1673-5374.390965
Vancouver
Dong W, Liu S, Li S, Wang Z. Cell reprogramming therapy for Parkinson’s disease. Neural Regeneration Research. 2024;19(11):2444-2455. doi:10.4103/1673-5374.390965
BibTeX
@article{Dong2024,
author = {Dong, Wenjing and Liu, Shuyi and Li, Shangang and Wang, Zhengbo},
title = {Cell reprogramming therapy for Parkinson’s disease},
journal = {Neural Regeneration Research},
year = {2024},
volume = {19},
number = {11},
pages = {2444--2455},
doi = {10.4103/1673-5374.390965}
}
EUVIMED